Characterization of cancer stem cells in chronic myeloid leukaemia.
about
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreThe Role of MicroRNAs in Myeloproliferative NeoplasiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cellsChronic myeloid leukemia: mechanisms of blastic transformationDestabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia.Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis.Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in miceHomoharringtonine and omacetaxine for myeloid hematological malignancies.Cancer stem cell genomics: the quest for early markers of malignant progression.Dasatinib: is it all in the dose?Targeted therapy of chronic myeloid leukemia.Myeloproliferative neoplasms: new translational therapies.Mechanisms of resistance to BCR-ABL kinase inhibitors.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.Targeting a chronic problem: elimination of cancer stem cells in CMLGene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential.Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway.Wool-Like Hollow Polymeric Nanoparticles for CML Chemo-Combinatorial Therapy.
P2860
Q24569706-457565CF-FE62-439F-B833-1E808E788EE6Q26739435-0B899F68-B613-43A1-A344-F66170B38090Q27028181-FB8FDB94-4A71-4CF6-A24B-D146FC3ADF1CQ33397085-C4E634EC-692F-4988-A3D7-893BAC44CB9EQ33806036-495AC6A6-6A1E-45E9-AF1A-1505B564ABDBQ33968037-BD0E2E5F-4055-451C-8474-B3FD2488A571Q34082540-F1B1BDA5-AC89-416B-BDC4-95B703E2BBAAQ34183433-311CD663-BB16-43F7-8EBF-FBC31872CBA6Q34348134-090643A0-E649-43DF-8D88-A19C18578A85Q34631681-88F5C9DF-2D84-4AE2-BF78-0A07278755C3Q34771074-39A0E2FA-8F50-4F0D-B1A9-2EF22B531717Q35692793-6E889B3A-026C-40D4-8911-5D666765A37AQ37132850-5BA9E40D-BE22-4499-85EA-924365BBF76DQ37206241-F661BFD1-D218-4C68-85C5-A07C5DBB06E2Q37303829-5924F0BE-95DE-4466-8F1B-6D66A886AF61Q37446279-C2A82A7D-A21A-4702-8A30-EBED43E8593CQ37592247-F2FCCBE9-E218-4614-87A3-E9FDBD397737Q37707362-30180955-CADC-4DD4-81DA-95E8B1DFB81AQ37752572-266AD45B-D70E-4364-870A-218EFC60B6FDQ37812070-433E65B3-19D2-43E6-B24F-AE5F2817130EQ37836923-93F3F008-2DFB-4B36-AECF-F0ADC71F45DAQ37836931-CF9D2C04-02CC-4F13-9107-13622B7BE1BEQ37911537-F6B871D3-79B9-4E79-B086-AEE4F38EAA3FQ38133575-B7914A9C-2440-4BC6-9402-DA61B0A8ABDFQ39126141-C9DB6F89-FCE8-4D78-9810-EB23F8CDC973Q41899036-A84A5473-BA7D-4D9F-985F-D993AC3B036FQ41964099-7671B512-8E58-44B2-AEBE-C4D59F7DD6B4Q47107358-30544371-1C14-4438-9247-EB302118E322Q47440281-CAE3635E-3FCA-4291-929A-69DD79F5F6C3Q48505242-71D9D356-EA01-4BBB-8B8D-4166F9276926Q52579601-CCF1F928-DB3C-4FA5-A770-EB2AC6E5BF78
P2860
Characterization of cancer stem cells in chronic myeloid leukaemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Characterization of cancer stem cells in chronic myeloid leukaemia.
@ast
Characterization of cancer stem cells in chronic myeloid leukaemia.
@en
Characterization of cancer stem cells in chronic myeloid leukaemia.
@nl
type
label
Characterization of cancer stem cells in chronic myeloid leukaemia.
@ast
Characterization of cancer stem cells in chronic myeloid leukaemia.
@en
Characterization of cancer stem cells in chronic myeloid leukaemia.
@nl
prefLabel
Characterization of cancer stem cells in chronic myeloid leukaemia.
@ast
Characterization of cancer stem cells in chronic myeloid leukaemia.
@en
Characterization of cancer stem cells in chronic myeloid leukaemia.
@nl
P356
P1476
Characterization of cancer stem cells in chronic myeloid leukaemia
@en
P2093
H G Jørgensen
T L Holyoake
P304
P356
10.1042/BST0351347
P577
2007-11-01T00:00:00Z